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Summary Background The phase I program of anticancer
agents usually consists of multiple dose escalation studies
to select a safe dose for various administration schedules.
We hypothesized that pharmacokinetic and pharmacody-
namic (PK–PD) modeling of an initial phase I study (stage 1)
can be used for selection of an optimal starting dose for
subsequent studies (stage 2) and that a post-hoc PK–PD
analysis enhances the selection of a recommended dose for
phase II evaluation. The aim of this analysis was to
demonstrate that this two-stage model-based design, which
doesnotinterfereintheconductoftrials,issafe,efficientand
effective. Methods PK and PD data of dose escalation
studies were simulated for nine compounds and for five
administration regimens (stage 1) for drugs with neutrope-
nia as dose-limiting toxicity. PK–PD models were devel-
oped for each simulated study and were used to determine a
starting dose for additional phase I studies (stage 2). The
model-based design was compared to a conventional study
design regarding safety (number of dose-limiting toxicities
(DLTs)), efficiency (number of patients treated with a dose
below the recommended dose) and effectiveness (precision
of dose selection). Retrospective data of the investigational
anticancer drug indisulam were used to show the applica-
bility of the model-based design. Results The model-based
design was as safe as the conventional design (median
number of DLTs=3) and resulted in a reduction of the
number of patients who were treated with a dose below the
recommended dose (−27%, power 89%). A post-hoc
model-based determination of the recommended dose for
future phase II studies was more precise than the conven-
tional selection of the recommended dose (root mean
squared error 8.3% versus 30%). Conclusions A two-stage
model-based phase I design is safe for anticancer agents
with dose-limiting myelosuppression and may enhance the
efficiency of dose escalation studies by reducing the
number of patients treated with a dose below the recom-
mended dose and by increasing the precision of dose
selection for phase II evaluation.
Keywords Oncology.PhaseItrialdesign.Optimaldesign.
Doseescalation.Dosefinding.Pharmacokinetics.
Pharmacodynamics.Modelingandsimulation
Introduction
The design of phase I dose escalation studies for experi-
mental cytotoxic agents has extensively been discussed in
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London, UKthe past decades. For safety issues, the initial dose level is
usually far below the anticipated recommended dose. In the
conventional algorithm-based design, which uses modified
Fibonacci escalation and three patients per cohort, this
may result in treatment of many patients with a dose
below the recommended dose [1, 2]. A second disadvan-
tage of the conventional design is the imprecise estimation
of the recommended dose due to the limited number of
patients at doses in the range of the recommended dose [3].
Various model-based modifications of the conventional
method have been proposed, such as the continual
reassessment method (CRM) [2], dose escalation with
overdose control [4], the random walk rule [5] and decision
theoretic approaches [6]. These model-based methods
generally treat fewer patients at a dose level below the
recommended dose and result in a more precise estimate of
the recommended dose.
Although model-based approaches offer a promising
alternative to the conventional phase I clinical trial designs
in oncology, these methods are seldomly used in practice,
which is largely due to operational difficulties and lack of
prospective validation [7]. In order to avoid practical
problems, He et al. [8] proposed a post-hoc model-based
determination of the recommended dose using results from
conventional Fibonacci dose escalation trials. This method
allowed precise determination of the recommended dose
without interfering in the conduct of the trial. Adversely, in
their analysis, the number of patients treated at suboptimal
dose levels was not optimized by this post-hoc analysis.
During phase I development, various administration
regimens are commonly evaluated. The regimen with the
best tolerability, convenience and highest dose intensity is
selected for further development. Dose escalation studies
are usually performed in parallel to select the appropriate
dose for each administration regimen and to accelerate
clinical development.
A two-stage model-based design is proposed for the
phase I program of novel anticancer agents. The first stage
of the model-based design is the conduct of a single phase I
study using conventional modified Fibonacci-like dose
escalation. During a model-based interim analysis, data
from the first phase I trial are used to optimize the design of
subsequent studies prior to their initiation. Optimization of
the second stage of the design will be attained by (1)
development of a pharmacokinetic and pharmacodynamic
population model using data from the first stage and (2) a
simulation study using the developed model, which will
confer a safe dose to start dose escalation with alternative
administration regimens. After the conduct of all dose
escalation studies, the recommended doses for further
clinical evaluation will be determined in a post-hoc
analysis, which may enhance the effectiveness (precision
of dose selection) of the phase I program.
The conduct of all dose escalation studies in this two-
stage design is identical to the conduct of a classical dose
escalation study. Only the starting doses during the second
stage may be higher. The major advantage of the higher
starting doses in the proposed two-stage model-based
design is a potential reduction of the number of patients
to be treated at a dose level below the recommended dose.
In addition to the ethical benefit, this may also result in a
reduction of cost and time to complete a dose escalation
study.
The two-stage model-based design may be applied to
investigational anticancer agents with well defined dose-
limiting toxicity related to drug exposure. In the current
analysis, the two-stage model-based design was applied to
anticancer agents with dose-limiting myelosuppression.
Neutropenia is a common dose-limiting toxicity for cyto-
toxic agents and may cause serious infections, which may be
fatal. The neutrophil count over time can be related to drug
exposure by a semi-physiological pharmacokinetic and
pharmacodynamic (PK–PD) model [9]. The PK–PD char-
acteristics of drugs with dose-limiting myelosuppression
can thus be described by integrated PK–PD models.
Therefore, anticancer agents with dose-limiting neutropenia
were suitable compounds to demonstrate the potential of
the proposed model-based analyses.
Simulation studies were performed to evaluate the two-
stage model-based design. The objectives of this research
were to demonstrate that (1) the number of patients treated
at a dose level below the recommended dose can be
reduced by the proposed model-based analysis and that (2)
the two-stage model-based design can be safely used to
optimize the design of dose escalation studies in oncology.
The performance of the two-stage model-based design was
retrospectively evaluated using clinical data of the phase I
program of the investigational anticancer drug indisulam.
Methods
The design of the simulation study is shown in Fig. 1. Steps
1 to 5 are explained into detail below.
Simulation of pharmacokinetic and pharmacodynamic
data (step 1)
PK and PD data were simulated for nine compounds with
various pharmacokinetic profiles. (Figure 2) A three-
compartment model was used with or without saturable
elimination and with or without auto-induction. (Figure 3)
Drug elimination was described by the Michaelis Menten
parameters Vmax (maximal elimination rate) and Km
(concentration related to half-maximal elimination). Km
was relatively low (1 mg/L) or relatively high (100 mg/L)
62 Invest New Drugs (2010) 28:61–75representing saturable and linear drug elimination, respec-
tively. Auto-induction was described by an enzyme turnover
model. Drug concentrations in the central compartment were
related to an increased input rate into the enzyme compart-
ment, resulting in an increased concentration of a hypothet-
ical amount of enzyme and a proportional increase of the
drug elimination rate. Drug elimination was maximally
induced by 100% (Imax), the effective concentration related
to half-maximal induction (ECI50) was 1 mg/L and the
mean turnover time of the enzyme (MTTenzyme) was 24 h.
The distribution volumes of the peripheral compartments
were relatively small (1 L) or relatively large (10 L) to vary
the magnitude of drug distribution. Inter-individual and
residual random effects were moderate or large. (Table 1)
The differential equations of the pharmacokinetic models
are given below.
V1  
dC1
dt
¼  Vmax  
C1
C1 þ Km
  A4   Q2   C1 þ Q2   C2
 Q3   C1 þ Q3   C3
ð1Þ
V2  
dC2
Dt
¼ Q2   C1   Q2   C2 ð2Þ
V3  
dC3
dt
¼ Q3   C1   Q3   C3 ð3Þ
dA4
dt
¼ kenz in   1 þ Imax  
C1
C1 þ ECI50
  
  kenz out   A4 ð4Þ
The dose-limiting toxicity of all virtual compounds was
neutropenia. The time course of drug-related neutropenia
was described by a semi-physiological population pharma-
codynamic model that was developed by Friberg et al. [9]
(Fig. 3). This model comprised a progenitor compartment
of proliferating blood cells, three transit compartments
representing the maturation chain in the bone marrow and a
compartment corresponding to the central circulation. The
model comprised two system related parameters: the mean
transit time (MTT) and a feedback parameter gamma (γ).
The MTT was the average time between neutrophil
proliferation and completion of maturation and was related
to the first order transition rate constant ktr (=4/MTT). The
feedback parameter γ represented the induction of stem cell
proliferation by endogenous growth factors and/or cyto-
kines [10]. The baseline blood cell count was estimated
from the observed baseline value and a residual error. The
Fig. 1 Flow-chart showing the
design of this study and the
corresponding outcome
parameters
ð1Þ
Invest New Drugs (2010) 28:61–75 63proliferation rate was reduced by drug exposure in the
central pharmacokinetic compartment according to a linear
function (Eq. 5).
kprol¼ktr   1   slope   C1 ðÞ ð 5Þ
Using the PK–PD parameters from Table 1, data for dose
escalation studies were simulated. The design of the
simulated dose escalation studies was in accordance with
the design of classical phase I studies [11]. Patients were
treated in silico in three-patient cohorts, that were extended
to six-patient cohorts if significant (≥CTC grade 2) toxicity
was observed. Neutrophil counts were simulated with
alternating 3 and 4 day intervals (twice weekly). A
modified Fibonacci-like dose escalation strategy was used
[1]. The dose was escalated by 100% if no or minimal
(CTC grade 0 or 1) neutropenia was observed. If one or
more patients had CTC grade 2 toxicity, the dose was
escalated by 50% increments and if serious (CTC grade 3
or 4) neutropenia was observed, the dose was escalated by
25%. Dose-limiting neutropenia was defined as CTC grade
4 neutropenia (absolute neutrophil count ≤0.5×10
9 per
liter) during at least two subsequent hematological meas-
urements (∼1 week). If two or more patients in a six-patient
cohort experienced dose-limiting neutropenia, this dose
level was defined as the non-tolerated dose (NTD). The
recommended dose for future studies was the dose level
immediately below the NTD.
Dose escalation studies were simulated for five admin-
istration regimens:
1. A single 1-h infusion (D×1) every 3 weeks
2. Daily 1-h infusions on days 1–5 (D×5) every 3 weeks
3. Weekly 1-h infusions on days 1, 8, 15 and 22 (W×4)
every 6 weeks
4. A 120-h infusion (120 H) every 3 weeks
5. A continuous infusion during 3 weeks (CI)
Regimens 1–4 were evaluated in the phase I program of
indisulam, that was used in this study as a real dataset for a
Fig. 2 Typical pharmacokinetic
profiles after treatment with a
1-h infusion of the highest (non-
tolerated) dose of all virtual
compounds. a compound 1; b
compounds 2, 3, 4, 5; c com-
pound 6, d compound 7; e
compound 8; f compound 9
64 Invest New Drugs (2010) 28:61–75retrospective evaluation of the two-stage model-based
design [12]. These regimens comprised short and long
infusions, single and multiple drug administrations and
were therefore selected for the current study. Schedule 5,
the continuous infusion, was added to cover the full range
of short exposure to continuous exposure regimens.
Pharmacokinetic data were simulated according to rich
sampling designs as commonly used in phase I trials. PK
samples were taken during infusion at fixed time points.
Additional PK samples were taken after infusion and were
logarithmically spaced between the end of infusion and the
last sampling point. The last sampling point corresponded
to five times the mean residence time (MRT) after the end
of infusion. To mimic the fact that limited knowledge may
be available at the start of first in human studies, the true
MRT was perturbed by a geometric standard deviation of
1.70 to account for prediction uncertainty. This standard
deviation was derived from previous publications [13, 14].
The limit of quantitation (LOQ) was 50 ng/mL for all
compounds. Data below the LOQ were excluded from data
analysis.
Dose escalation studies with a modified Fibonacci-like
escalation scheme (see above) were performed in silico
for five administration regimens for each of the nine
compounds. In total, 45 phase I studies were simulated
using NONMEM (version VI, GloboMax, Hanover, MD,
USA). Parameters with inter-individual variability were
log-normally distributed. Data were logarithmically trans-
formed and residual errors were additive on a logarithmic
scale.
PK–PD model development (step 2)
Pharmacokinetic and pharmacodynamic models were de-
veloped for each of the 45 simulated data sets. The
investigator was blinded to the ‘true’ PK–PD models that
were defined by the parameters in Table 1.
Pharmacokinetic and pharmacodynamic data were
analyzed sequentially. For PK–PD analysis, a data set
was used that contained all dosing information and all
pharmacokinetic and pharmacodynamic measurements.
Pharmacokinetic parameters were fixed to the estimates
of the pharmacokinetic analysis. This method has been
described into more detail by Zhang et al. [15].
The estimation of the system parameters MTT and γ and
the interindividual variability of MTT was supported by
prior knowledge of the values of these parameters. The
Bayesian priors were the geometric means of the estimates
that were reported for various other anticancer agents by
Friberg et al. (MTT=116 h, γ=0.167, IIV MTT=22.4%).
Prior uncertainty corresponded to the geometric standard
deviation of these estimates (MTT 18%, γ 59%, IIV MTT
20%) [9].
All parameters (P) were assumed to be log-normally
distributed in the study population. Consequently, interin-
dividual variability was estimated using an additive
function on a logarithmic scale (ln(Pi)=ln(TVP)+ηi)t o
describe the individual deviation (ηi) from the population
typical value (TVP). Differences between observed and
individual predicted values were modeled as additive
residual errors on a logarithmic scale. Data were analyzed
with the first-order conditional method using NONMEM
(version VI, GloboMax, Hanover, MD, USA). Discrimina-
tion between hierarchical models was based on the
objective function value, goodness of fit plots and standard
errors of parameter estimates.
Standard errors and measures of correlation between
parameter estimates were obtained using the COVARI-
ANCE option of NONMEM.
Prediction of safe starting dose (step 3)
The PK–PD models, that were developed in step 2 using data
from a single in silico phase I study (simulated in step 1),
were used to predict the outcome of subsequent dose
escalation studies. For instance, the model that described
the PK–PD data of compound 1 after a single 1-h infusion,
was used to predict the recommended doses for the other
four administration regimens for compound 1. Trial simu-
lations were carried out to make these predictions. For each
prediction, a dose escalation trial was simulated in 40,000-
kcirc
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Fig. 3 Structural pharmacokinetic model of the nine virtual com-
pounds and the semi-physiological model describing the time profile
of absolute neutrophil counts (ANC) after treatment with myelosup-
pressive chemotherapy
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estimates and for variability between patients. A total
number of 200 sets of PK–PD parameters from the final
parameter estimates, their geometric standard errors and the
correlation matrix were selected. For each set of PK–PD
parameters, 200 trials were simulated with different random
selections of patients.
One tenth of the predicted non-tolerated dose is
conventionally considered a safe starting dose for dose
escalation studies. Therefore, in order to determine the
starting dose of a dose escalation trial, the non-tolerated
dose of the previous trial was multiplied by 10% and
perturbed using a geometric standard deviation of 1.54.
The perturbation accounted for uncertainty in the pre-
dicted tolerability of anticancer agents prior to first in man
studies. The geometric standard deviation was calculated
from predicted and empirically determined non-tolerated
doses of 21 anticancer drugs [16–19]. Patients were
treated in three- or six-patient cohort and the modified
Fibonacci-like dose escalation strategy was used (see
above for details).
The median value of each set of 40,000 recommended
doses was the predicted recommended dose. The five and
95 percentiles formed the 90% confidence intervals of the
prediction. The lower boundary was considered the safe
starting dose for an in vivo clinical dose escalation study.
Table 1 Pharmacokinetic and pharmacodynamic parameters of the nine virtual compounds
Compound 1 2 3 4 5 6 7 8 9
Summary of PK–PD characteristics
Compartments
a 122222233
Saturable
elimination
b
–– – – – + –––
Auto-induction ––––––+ – +
IIV PK Moderate Moderate Large Moderate Moderate Moderate Moderate Moderate Large
IIV PD Moderate Moderate Moderate Large Moderate Moderate Moderate Moderate Large
Residual error PK Moderate Moderate Moderate Moderate Large Moderate Moderate Moderate Moderate
PK parameters
V1
c (L) 10 10 10 10 10 10 10 10 10
Vmax
c (mg/h) 100 100 100 100 100 10 100 100 100
Km (mg/L) 100 100 100 100 100 1 100 100 100
V2
c ( L ) 1 1 01 01 01 01 01 01 01 0
Q2 (L/h) 5 5 5 5 5 5 5 5 5
V3
c ( L ) 11111111 0 1 0
Q3 (L/h) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Imax ( % ) 000000101
ECI50 (mg/L) 1 1 1 1 1 1 1 1 1
MTTenz (h) 24 24 24 24 24 24 24 24 24
IIV V1; V2; V3
d (%) 40 40 80 40 40 40 40 40 80
IIV Vmax
d (%) 30 30 60 30 30 30 30 30 60
IIV Q2; Q3
d (%) 30 30 60 30 30 30 30 30 60
IIV MTTenz
d (%) 25 25 50 25 25 25 25 25 50
Residual error PK
e (%) 20 20 20 20 40 20 20 20 20
PD parameters
Slope (mg/L) 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
MTT (h) 120 120 120 120 120 120 120 120 120
Base (10
9/L) 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3
Gamma 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17
IIV slope
d (%) 45 45 45 90 45 45 45 45 90
IIV MTT
d (%) 25 25 25 25 25 25 25 25 25
IIV base
d (%) 35 35 35 35 35 35 35 35 35
Residual error PD
e (%) 45 45 45 45 45 45 45 45 45
aAll data were simulated from three compartment models, but the contribution of one or both peripheral compartments was small for compounds
1–7
bAll data were simulated from a model with Michaelis Menten elimination, but saturation was only evident if Km was relatively low (1 mg/L)
cAllometric scaling was applied to Vmax ((WT/70)
0.75) and to the volumes of distribution V1, V2, V3 ((WT/70)
1)
dIIV = inter-individual variability; geometric standard deviations are listed
eResidual errors were additive on a logarithmic scale; geometric standard deviations are listed
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using simulated data (step 4)
Using the true PK–PD parameters (Table 1) and starting
doses that were considered safe for clinical dose escalation
studies, 1,000 replicate trials were simulated (two-stage
model-based design). In addition, 1,000 replicate trials were
simulated with starting doses perturbed around 10% of the
recommended dose (conventional method).
The number of patients with dose-limiting neutropenia
was assessed for both methods as a measure of safety of the
two-stage model-based design. The median number of
patients treated with a dose below the recommended dose
was compared between the new and the conventional
methods, for each virtual compound and for each admin-
istration regimen, as a measure of efficiency of the two-
stage model-based design. The two-stage model-based
design was considered successful if it did not result in an
increased number of patients with dose-limiting neutrope-
nia and if the number of patients treated with a dose below
the recommended dose was reduced.
Post-hoc determination of recommended dose (step 5)
Based on the phase I program of a novel anticancer agent, a
recommended dose must be defined for further testing in
phase II clinical studies. In a conventional study design, the
selection of the recommended dose is empirically based on
clinical outcome and is defined as the highest dose level
with more than two out of six patients with dose-limiting
toxicity. In the two-stage model-based design, the recom-
mended dose for phase II studies is based on a PK–PD
analysis using all PK–PD data from phase I. This PK–PD
analysis should be performed after finalization of the
clinical phase I program and is therefore termed a post-
hoc analysis.
To evaluate this part of the two-stage model-based
design, the PK–PD models of each compound were
updated using the data from all five phase I studies that
were simulated in step 1 (Fig. 1). The updated models were
used for the simulation of 40,000 dose escalation studies for
each administration regimen. Parameter uncertainty and
variability between patients were taken into account. The
median value of the 40,000 simulated recommended doses
was proposed for further testing in phase II studies. This
method was used to select a recommended dose for all
compounds (n=9) and for all administration regimens (n=5).
The 45 selected recommended doses (Drec.,pred)w e r eu s e dt o
determine the precision of this strategy. The root mean
squared relative prediction error (RMSE%) was calculated as
a measure of precision (Eq. 6). The true recommended dose
(Drec.,true) was defined as the median value of 1,000
simulated recommended doses using the true PK–PD model,
conventional starting doses (i.e. the recommended dose of
the previous trial multiplied by 10% and perturbed using a
geometric standard deviation of 1.54) and the modified
Fibonacci-like dose escalation strategy.
RMSE% ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X Drec:;pred   Drec:;true
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The precision of the two-stage model-based design was
compared to the precision of the conventional design,
where the recommended dose was based on the clinical
outcome of a dose escalation study. The RMSE% of the
conventional design was calculated for the 1,000 simulated
recommended doses from the true PK–PD model (Drec.,pred)
and their median value (Drec.,true).
The precision of the selection of the recommended dose
for phase II evaluation was also assessed for the PK–PD
models that were developed using data from a single phase I
study.
Evaluation of the two-stage model-based design
using clinical data of indisulam
The previously conducted phase I program of the investi-
gational anticancer agent consisted of four dose escalation
studies of four administration regimens: D×1, D×5, W×4,
120 H [20–23]. Neutropenia was identified as the dose-
limiting toxicity [20–23]. It was verified retrospectively if
the number of patients treated with a dose below the
recommended dose could have been reduced by the
proposed two-stage model-based design. For each of
the phase I studies, a PK–PD model was developed using
indisulam plasma concentrations and absolute neutrophil
counts that were measured during the first treatment cycle.
The models were used to simulate 40,000 dose escalation
studies for the alternative administration regimens, taking
into account parameter uncertainty (×200) and variability
between patients (×200). The median values were selected
as the predicted recommended doses and the five percen-
tiles were considered safe starting doses for the other three
administration regimens. The selected starting doses were
compared to the clinically determined recommended and
non-tolerated doses. The number of patients treated at dose
levels below the clinically determined recommended doses
was assessed. In this retrospective evaluation, the two-stage
model-based design was considered successful if all
selected starting doses were below the highest administered
dose levels and if the number of patients treated with at a
dose level below the recommended dose was reduced by at
least 10%.
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Simulation of pharmacokinetic and pharmacodynamic
data (step 1)
In total, 45 phase I dose escalation studies were simulated.
These studies each comprised five to 12 dose levels and
18–55 patients, and were considered representative for
clinical phase I studies in oncology. In each study, two to
seven patients experienced dose-limiting toxicity.
PK–PD model development (step 2)
For each simulated study, a pharmacokinetic model was
successfully developed. One-, two- and three compart-
ment models were selected with or without saturable
elimination. Table 2 shows the structural PK models that
were selected for all simulated data sets. Saturable
elimination was correctly identified, irrespective of the
administration schedule. Auto-induction could not be
demonstrated for any of the simulated data sets (see
“Discussion”). For compounds 8 and 9, three-compartment
models were selected for the 1-h infusion schedules, but
identification of the third compartment was less success-
ful for the 120-h and continuous infusions (Table 2). The
true PK model of compound 1 consisted of a single
relevant compartment (Table 1), but the minor second
compartment could be identified based on data from the
W×4 schedule (V2=1.58 L and Q2=0.87 L/h). Using data
from the 120 H schedule, a second compartment could
also be identified for compound 1, but the intercompart-
mental clearance was large and the model proved to be
equivalent to a one-compartmental model (V1=6.8 L, V2=
5.3 L and Q2=19.9 L/h).
Prediction of safe starting dose (step 3)
This part of the study was most computer-time intensive
with the simulation of 40,000 clinical trials for each
scenario. In Fig. 4a, the distribution of the simulated
recommended dose for the D×1 regimen of compound 2
(n=40,000) is shown for the PK–PD model that was
developed based on data from a W×4 phase I dose
escalation study. The variability of this distribution is
explained by variability between patients and by uncertain-
ty of the PK–PD parameter estimates. Figure 4b shows the
simulated recommended doses for one set of PK–PD
parameter estimates (n=200). The variability in Fig. 4bi s
explained by variability between patients. The large
variability in Fig. 4b indicates that the uncertainty of PK–
PD parameter estimates (3.4–60%) had a minor contribu-
tion to the overall variability of the simulated recommended
doses. The five-percentiles were considered safe starting doses
for stage 2 of the model-based design (step 4, Fig. 1).
Table 2 The structural pharmacokinetic models that were selected for each phase I study ( )
The compound numbers correspond to the numbers in Table 1. The black margins correspond to the “true” models that were used for data
simulation
Fig. 4 Simulated recommended
doses of a 1-h infusion of
compound 2, based on a PK–PD
model that was developed using
PK–PD data from a W×4 dose
escalation study. a The frequen-
cy distribution of all 40,000
simulated doses (variability
comprises variability between
patients and uncertainty of PK–
PD parameter estimates). b The
frequency distribution of 200
simulated doses for a single set
of PK–PD parameter estimates
(variability comprises variability
between patients)
68 Invest New Drugs (2010) 28:61–75Regarding the scenario depicted in Fig. 4, 158 mg was
selected as the starting dose for the D×1 regimen of
compound 2. This was 49% of the median recommended dose
320 mg. For all scenarios, the proposed starting doses were
between 33% and 56% of the median recommended doses.
The median values and the five-percentiles of the
s i m u l a t e dr e c o m m e n d e dd o s e sa r ep l o t t e di nF i g .5 for all
scenarios. The doses in Fig. 5 are normalized to the true
recommended dose, which was defined as the median
value of 1,000 simulated recommended doses using the
true PK–PD model. All starting doses that were proposed
for stage 2 of the model-based design were below the true
recommended dose.
Evaluation of the two-stage model-based design
using simulated data (step 4)
Figure 6 shows the number of dose-limiting toxicities for
the conventional design and for the various scenarios of the
two-stage model-based design (median and ten to 90
percentile range). When the model-based starting doses
were used in clinical trial simulations, the mean number of
dose-limiting toxicities per dose escalation study ranged
from 2.9 to 3.6 for the various scenarios. For the
conventional design, the mean number of dose-limiting
toxicities per study was between 3.0 and 3.6. The number
of DLTs was relatively small for compound 6 with saturable
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Fig. 5 The predicted recommended dose (median of 40,000 replicate
values) and proposed starting dose (five-percentile of 40,000 replicate
values) based on PK–PD models that were developed using data from
a single phase I study, relative to the true recommended dose.
Predicted recommended doses and starting doses are plotted for all
compounds (1: □;2 :* ;3 : +;4 :Δ;5 :⁃;6 :▬;7 :✕;8 :○;9 :◊) and for
all regimens (a D×1; b D×5; c W×4; d 120 H; e CI)
Invest New Drugs (2010) 28:61–75 69Fig. 6 Median and ten to 90 percentiles ranges of the number of patients with dose-limiting toxicity for the conventional design (◊) and for
stage 2 of the model-based design (stage 1: D×1 ▪;D × 5▴;W × 4✕; 120 H *; CI ●) for all regimens and for all compounds
Fig. 7 Median and interquartile ranges of the number of patients treated with a dose below the recommended dose for the conventional design (◊)
and for stage 2 of the model-based design (stage 1: D×1 ▪;D × 5▴;W × 4✕; 120 H *; CI ●) for all regimens and for all compounds
70 Invest New Drugs (2010) 28:61–75elimination. This may reflect the more than proportional
increase in drug exposure when the dose is escalated to the
next dose level, which may result in a sharp increase in
incidence of DLT at the first dose level above the recom-
mended dose.
The number of patients who were treated at a dose level
below the recommended dose, was on average 20.5 when a
dose escalation study was started at a conventional starting
dose level. The two-stage model-based design resulted in a
reduction of this number to 13.0 patients. Figure 7 is a
graphical representation of the number of patients treated at
a dose level below the recommended dose (median and
inter-quartile range). For all scenarios, this number was
higher for the conventional study design (first plot of each
sextet in Fig. 7) as compared to the two-stage model-based
design.
For a complete phase I program, comprising of one
conventional study at stage 1 followed by four studies with
a model-based starting dose at stage 2, the reduction of the
number of patients treated at a dose below the recommen-
ded dose was on average 27.2%. This was consistent for the
various scenarios that were evaluated (range 12.2–39.8%).
The power of the two-stage model-based design to include
fewer patients at dose levels below the recommended dose
was 88.6%.
The starting dose was not tolerated in 1.3% of the
simulated conventional dose escalation studies. When the
starting dose in stage 2 was based on data from stage 1,
the initial dose level was not tolerated in only 0.3% of the
simulated trials.
Post-hoc determination of recommended dose (step 5)
The PK–PD models were successfully updated using PK–
PD data from all five dose escalation studies. More
complex structural PK models could be selected for
compounds 1, 3, 5 and 7 (Table 3). Figure 8 shows the
recommended doses that were proposed for phase II
Table 3 The structural pharmacokinetic models that were selected for
the combined data of all studies ( )
The compound numbers correspond to the numbers in Table 1. The
black margins correspond to the “true” models that were used for data
simulation
Fig. 8 Visual representation of the precision of the selection of the
recommended dose for the conventional method (ten to 90 percentile
range of simulated empirically determined recommended doses,
RMSE 30.0%) and for the two-stage model-based design (▴, RMSE
8.3%). The recommended doses that were predicted using data from a
single phase I study, are also indicated (✕, RMSE 11.9%)
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‘true’ recommended doses that were determined using
the true PK–PD models. The precision of the selection of
the recommended dose for phase II studies, expressed as the
RMSE, was 8.3% for the post-hoc model-based dose
selection. Conversely, the precision was only 30% for the
conventional study design (ten to 90 percentile ranges
are indicated in Fig. 8). If the recommended doses were
determined by the post-hoc model-based method, using
the PK–PD models that were based on data from a single
phase I, the precision was 12% (Fig. 8).
Evaluation of the two-stage model-based design
using clinical data of indisulam
Pharmacokinetic data of indisulam (n=3,327) were available
from four phase I studies and from 143 patients [20–23]. The
pharmacokinetic data for each phase I study were best
described by three-compartment models with saturable
elimination and saturable distribution. This model was
described in detail in a previous publication from our group
[12]. A model with a linear and a saturable elimination
pathway adequately described the pharmacokinetic data from
the D×5, the W×4 and the 120 H dose escalation studies.
Conversely, the data from the D×1 study did not contain
sufficient information to identify the linear elimination
pathway. Therefore, a reduced model without a linear
elimination pathway was used to describe the data from the
D×1 study. Measurements of the absolute neutrophil count
(n=1,114) were available from 145 patients and could be
adequately described by the semi-physiological model of
neutropenia. (Figure 3)[ 24] The MTT of neutrophils (Fig. 3)
was estimated at 191 h for the W×4 regimen. For the other
regimens, this parameter estimate was closer to the Bayesian
prior (D×1: 147 h; D×5: 137 h; 120 H: 134 h).
In Fig. 9, the course of the dose escalation studies of
indisulam is depicted for all administration regimens. The
recommended doses that were determined in the clinical in
vivo studies are indicated by a black dashed line [20–23].
The starting doses that were selected retrospectively by trial
simulation using the four developed PK–PD models, were
all below the highest administered dose and were all above
the conventional starting dose.
The recommended doses that were predicted using the
final PK–PD model, based on data from all four phase I
studies, are indicated by ‘post-hoc’ in Fig. 9. The clinically
determined recommended doses were lower than these
post-hoc predictions for the D×5 and 120 H infusion
schedules and were higher for the D×1 and W×4
predictions. For indisulam, the ‘true’ PK–PD characteristics
and the ‘true’ recommended dose are unknown. Therefore,
it was not possible to determine the precision of the
selection of the recommended dose for the conventional
and the two-stage model-based design. Importantly, all
retrospectively selected starting doses would have been safe
for stage 2 of the model-based design.
Fig. 9 The course of the dose escalation studies of indisulam. For
each administration regimen (a D×1; b D×5; c W×4 and d 120 H),
the recommended dose (clinically determined during the phase I
program ; post-hoc estimate from final PK–PD model
) and the proposed starting doses ( ) are indicated
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studies, the number of patients treated at a dose level below
the recommended dose was 65 for the conventional design
(17 (D×1)+18 (D×5)+18 (W×4)+12 (120 H); Fig. 9). For
the D×1 schedule, inclusion of the first seven patients
would have been redundant if the starting dose would have
been based on data from the D×5 study. In addition, the two-
stage model-based design would also have resulted in a
reduction of six patients for the W×4 schedule and nine
patients for the 120 H schedule, if the D×5 study was
performed at stage 1. In total, 22 patients (34% of all
patients treated at a dose level below the recommended
dose) could have been treated at a higher dose level if the
two-stage model-based design would have been applied to
the phase I program of indisulam, starting with the D×5
schedule. If one of the other schedules would have been
selected for stage 1, the model-based design would have
resulted in a reduction of the number of patients treated at
a dose level below the recommended dose of 33 (51%),
28 (43%) or 14 (22%) for the D×1, W×4 and 120 H
schedules, respectively.
Discussion
A two-stage model-based design for optimization of the
phase I program of novel anticancer agents was proposed.
This simulation study demonstrated that the proposed two-
stage model-based design did not result in an increased
frequency of dose-limiting toxicities. Furthermore, the
two-stage model-based design resulted in a reduction of
the number of patients treated at a dose level below the
recommended dose. The precision of the selection of the
recommended dose for future phase II evaluation was
improved by a post-hoc model-based analysis.
The model-based design consists of two stages: an initial
phase I study conducted in a conventional manner (stage 1)
and subsequent phase I studies for alternative administra-
tion schedules, at starting doses that are based on advanced
PK–PD analysis. The starting doses for stage 2 of the phase
I program are determined by the five-percentiles of the
simulated recommended doses. This strategy was consid-
ered safe, because the likelihood that the starting dose
would be below the recommended dose, was close to 95%,
provided that the correct structural PK–PD model was
selected. In this study, we accounted for structural bias of
the PK model, because various structural PK models were
evaluated during model development. Structural model bias
was not taken into account for the semi-physiological
model of neutropenia. This was justified by previous
validation of the semi-physiological model of neutropenia
for a range of anticancer drugs with various mechanisms of
action [9, 25–28].
The semi-physiological model comprised a linear relation-
ship between the drug concentration and the proliferation rate
of neutrophils. Nevertheless, the nadir neutrophil count was
dependent to total drug exposure and the administration
schedule in a non-linear manner. This was mainly due to the
non-linear feedback mechanism in the model. The semi-
physiological characteristics of this model allowed successful
application to multiple administration schedules and dose
levels.
In this study, the two-stage model-based design was
evaluated for anticanceragents with dose-limiting neutropenia.
The two-stage model-based design may also be applicable to
drugs with other dose-limiting toxicities, provided that a PK–
PD relationship can be identified and quantified. An important
condition is, however, that the pharmacodynamic model
should permit extrapolation of the concentration–effect rela-
tionship to higher or lower levels of drug exposure and to
shorter or longer duration of drug exposure. Preferably, the
pharmacodynamic model should show consistency between
drugs and should be previously validated for similar com-
pounds. Hematological toxicity has been well characterized in
PK–PD models for multiple anticancer agents as opposed to
other types of toxicity, such as neurotoxicity, hand-foot
syndrome and diarrhea,and maytherefore bethe most suitable
adverse event for a successful application of the two-stage
model-based design.
Our aim was to optimize the efficiency and the efficacy
of phase I dose escalation studies, without interfering in the
conduct of the clinical trials. The dose escalation studies are
carried out in a conventional manner, but the starting dose
can be relatively higher as a result of optimal usage of all
available clinical PK and PD data by the application of
advanced PK–PD modeling. Contrary to CRM, this two-
stage model-based design does not require data analysis
during a dose escalation study. Consequently, it is expected
that this two-stage model-based design will not involve
operational or logistical difficulties.
Development of a PK–PD model using all phase I data,
followed by post-hoc determination of a recommended
dose for further evaluation in phase II clinical development
was proposed to maximize the precision of the determina-
tion of the recommended dose for future studies. This study
demonstrated that the precision was largely improved by
the model-based analysis: the RMSE was 8.3% for the two-
stage model-based design versus 30% for a conventional
study design. The high imprecision of the conventional
study design was also an important finding of this analysis.
Due to wide inter-patient variability and the limited number
of patients that is included in a phase I study, the outcome
of a clinical dose escalation study is subject to large random
variability.
A secondary goal of phase I clinical development is the
assessment of the pharmacokinetics of a novel compound.
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number of patients treated at low dose levels is reduced.
Depending on the schedule and the pharmacokinetic
properties of a compound, this may compromise the
characterization of the pharmacokinetics.
In this simulation study, auto-induction could not be
demonstrated in the interim PK models (step 2) that were
based on data from a single phase I study. Although the
effect size was large (up to 100% increase of the
elimination rate) in comparison to reported values for
anticancer agents (e.g. 36% increase of the elimination rate
of cyclophosphamide [29]), the effect of auto-induction was
not obvious in the pharmacokinetic profiles (Fig. 2d, f). In
addition, the value of mean turnover time of the inducible
enzyme was realistic (24 versus 12 h for ifosfamide [30]
and 45 h for cyclophosphamide [29]). It can therefore be
concluded that the poor identification of auto-induction was
not related to the PK parameters that were selected for the
compounds in this study.
To confirm the recommended dose that is selected in a
phase I trial, an enrichment phase may be added to the
conventional study design, where additional patients are
included at the recommended dose. The impact of an
enrichment phase was not evaluated in this analysis. In
addition, the conduct of a dose escalation study may be
influenced by a steering team of investigators to select the
dose escalation steps. The input of professionals is
undoubtedly more subtle than the modified Fibonacci-like
dose escalation strategy that was used in this simulation
study. For these two reasons, the precision of the selection
of a recommended dose for phase II studies may be
underestimated in this analysis.
The results of the simulation studies were confirmed by
retrospective evaluation using real clinical data. Indisulam
was used as a model compound. This drug has a highly
non-linear pharmacokinetic profile and indisulam-induced
neutropenia showed wide inter-patient variability. For these
PK–PD characteristics, indisulam was considered a suitable
compound to challenge the proposed model-based. The
two-stage model-based design resulted in the selection of
starting doses for stage 2 of the phase I program that were
all below the highest administered dose level and was
therefore considered safe. The efficiency of the phase I
studies could have been increased by application of the
two-stage model-based design and the phase I program
could have been conducted with 14 to 33 patients less. This
might have resulted in a reduction of cost and time for the
phase I development of indisulam.
This simulation study demonstrated that the proposed
two-stage model-based design is safe for anticancer agents
with dose-limiting myelosuppression. The two-stage model-
based design enhanced the efficiency of dose escalation
studies by an average 27% reduction of the number of
patients included at a dose level below the recommended
dose. The power of the proposed two-stage model-based
design to reduce the number of patients treated with a dose
below the recommended dose was 89%. The model-based
design was also effective in the precise selection of the
recommended dose for phase II evaluation. The good
performance of the model-based design seemed to be
irrespective of the administration schedule that was selected
for the dose escalation study at stage 1. The proposed two-
stage model-based design may enhance the early clinical
development of investigational anticancer drugs.
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